High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.
Authors: Álvarez-Pérez JC, Sanjuán-Hidalgo J, Arenas AM, Hernández-Navas I, Benitez-Cantos MS, Andrades A, Calabuig-Fariñas S, Jantus-Lewintre E, Paz-Ares L, Ferrer I, Medina PP
09/2025 - Nature communications